Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016

Watchlist Manager
Shanghai MicroPort Endovascular MedTech Group Co Ltd Logo
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Watchlist
Price: 91.42 CNY -1.8% Market Closed
Market Cap: 11.3B CNY

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Tax Provision
-ÂĄ144.9m
CAGR 3-Years
-37%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Tax Provision
-ÂĄ347.1m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
Tax Provision
-ÂĄ69.1m
CAGR 3-Years
-30%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Tax Provision
-ÂĄ167.6m
CAGR 3-Years
9%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Tax Provision
-ÂĄ264.7m
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-20%
Intco Medical Technology Co Ltd
SZSE:300677
Tax Provision
-ÂĄ146.1m
CAGR 3-Years
18%
CAGR 5-Years
30%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View

Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.

Intrinsic Value
137.35 CNY
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Tax Provision?
Tax Provision
-144.9m CNY

Based on the financial report for Sep 30, 2025, Shanghai MicroPort Endovascular MedTech Group Co Ltd's Tax Provision amounts to -144.9m CNY.

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 5Y
-36%

Over the last year, the Tax Provision growth was -35%. The average annual Tax Provision growth rates for Shanghai MicroPort Endovascular MedTech Group Co Ltd have been -37% over the past three years , -36% over the past five years .

Back to Top